# FDA Inspection 564301 - Celgene Corporation d.b.a. Abraxis Bioscience - February 18, 2009

Source: https://www.keypedia.com/records/fda_inspections/celgene-corporation-dba-abraxis-bioscience/35702f06-0b74-4565-9abc-0514e80f8adc
Source feed: FDA_Inspections

> FDA Inspection 564301 for Celgene Corporation d.b.a. Abraxis Bioscience on February 18, 2009. Classification: No Action Indicated (NAI).

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 564301
- Company Name: Celgene Corporation d.b.a. Abraxis Bioscience
- Inspection Date: 2009-02-18
- Classification: No Action Indicated (NAI)
- Project Area: Drug Quality Assurance
- Product Type: Drugs
- Office Name: Center for Drug Evaluation and Research

## Related Documents

- [FDA Inspection 976256 - 2016-06-30](https://www.keypedia.com/records/fda_inspections/celgene-corporation-dba-abraxis-bioscience/7840a953-b516-4fa0-b7a7-9fb9bc500c82)
- [FDA Inspection 884384 - 2014-06-24](https://www.keypedia.com/records/fda_inspections/celgene-corporation-dba-abraxis-bioscience/3e9a5538-f82e-4df0-8d19-5e6929ee1f62)

Company: https://www.keypedia.com/companies/celgene-corporation-dba-abraxis-bioscience/be6241ac-0d9c-45a2-8acb-5026fcde1b45

Office: https://www.keypedia.com/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c